Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THRIVE-132: Inclacumab for Reduced Re-admission in Sickle Cell Disease
NCT04927247Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Dec 2021
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of inclacumab in sickle cell disease (SCD), sponsored by Pfizer. Primary endpoint: Percentage of Participants With at Least 1 VOC That Required Admission to a Healthcare Facility and Treatment With Parenteral Pain Medication Within 90 Days of Randomization. Started Dec 2021; status: terminated.
02
Drugs
inclacumab
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT04927247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04927247.